Dr. Hamadani, is a Professor of Medicine and Director of the BMT & Cellular Therapy Program at the Medical College of Wisconsin, USA. His clinical and research focus is lymphoma, transplant and cellular therapy. He is the Scientific Director of Lymphoma Observation Research Program of CIBMTR, and the Co-Chair of the ASTCT Committee on Practice Guidelines. He has been lead investigator of a number of drug development trials and has authored over 350 peer reviewed manuscripts.
Professor Judith Trotman (MBChB, FRACP, FRCPA) is the Head of Haematology, Concord Hospital, University of Sydney. As a past ALLG Lymphoma Chair she maintains close collaborations with other lymphoma co-operative groups leading the ALLG’s contribution to the RATHL, REMARC, RELEVANCE PETReA and RADAR trials. She provides global leadership in charting the role of PET scanning in follicular lymphoma (PET in PRIMA, FOLLCOLL, GALLIUM, RePLy and PETReA studies). She has/is developing a number of digital initiatives with colleagues and patients, including the ClinTrial Refer smartphone App, the My Hodgkin My Health App, and the WhiMSICAL study – a global patient-derived database for patients with WM.
Sairah Ahmed, MD is a board-certified hematology and medical oncology physician and an Associate Professor in Cancer Medicine at the University of Texas, MD Anderson Cancer Center with a co-appointment in the Departments of Stem Cell Transplantation and Cellular Therapy and the Department of Lymphoma and Myeloma.
Dr Ahmed received her medical degree from Khyber Medical College and subsequently completed internship and residency in Internal Medicine at the University of Connecticut. She went on to hematology/oncology fellowship at Northwestern University in Chicago, Illinois and then stem cell transplant and cellular therapy fellowship at the University of Texas, MD Anderson to complete her training.
She serves in multiple leadership roles at the The University of Texas MD Anderson Cancer Center including the Inpatient Medical Director and Director of the CART program in the Lymphoma/Myeloma Department. She is a member of the American Society of Clinical Oncology, American Society of Hematology, and the American Society of Transplantation and Cellular Therapy and will be an incoming Co-Chair of the Cellular Immunotherapy for Cancers Working Committee of the Center for International Blood and Marrow Transplant Research. She has authored or coauthored at least 95 peer-reviewed journal articles and at least 5 book chapters. Dr. Ahmed’s clinical research focus includes Hodgkin lymphoma, cellular therapy/CART and survivorship in lymphoma.
Dr Anderson has been a practising clinical haematologist for the past ten years currently working both at The Royal Melbourne Hospital and The Peter MacCallum Cancer Centre. She is a foundation member of the CART consultant group at the Peter MacCallum Cancer Centre having joined the team at the inception of the unit in 2019. Dr Anderson obtained her PhD from the University of Melbourne in 2017 where she undertook extensive clinical and laboratory studies of a novel approach to treating B cell malignancies by harnessing apoptotic cell death with the agent now known as venetoclax. Since completion of her PhD Dr Anderson has continued her studies into mechanisms by which B cell malignancies evade targeted agents to develop therapeutic resistance. To further these studies Dr Anderson has relied on a multifaceted approach utilizing laboratory studies, clinical trial, and registry data to develop a multimodal understanding of how therapeutic resistance develops. Working primarily with difficult to treat B cell malignancies Dr Anderson has been well placed to harness the emerging technology of CART to benefit her patients. Dr Anderson brings her extensive clinical, laboratory and registry skills to help elucidate why and how some aggressive lymphomas develop resistance to CART. Dr Anderson is an internationally recognised author in the field of B cell malignancies and targeted therapies with more than 20 original publication in the last decade.
Farrukh Awan, M.D., is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of the Division of Hematology and Oncology at UTSW’s Harold C. Simmons Comprehensive Cancer Center where he leads the Lymphoid Malignancies Program. He specializes in stem cell transplant, cellular therapies and evaluation of novel therapies for the treatment of patients with lymphoid malignancies.
Dr. Awan completed a residency in internal medicine at the University of Pittsburgh Medical Center and received advanced training in hematology and oncology through a fellowship at The Ohio State University. He is certified by the American Board of Internal Medicine, the American Board of Medical Oncology, and the American Board of Hematology and is a member of several professional organizations, including the American Medical Association, the American Society of Clinical Oncology, and the American Society of Hematology. He is also the recipient of the Young Investigator Award from the American Society of Clinical Oncology and the Clinical Career Development Award from the Lymphoma Research Foundation.
Dr. Awan has delivered scores of presentations, administered multiple grants and clinical trials, and published numerous academic articles and book chapters.
Priv-Doz. Dr. Bröckelmann is a Resident Physician in hematology and medical oncology at the Department I of Internal Medicine and the German Hodgkin Study Group (GHSG) at the University Hospital of Cologne in Cologne, Germany. His research focuses on classical Hodgkin lymphoma with the aim to improve outcomes in the first-line and relapsed/refractory setting. Herein a major interest are clinical and translational studies to optimally harness the potential of immune checkpoint inhibition and other novel agents. He is additionally spearheading a consortium aimed to better understand mechanisms of immune-related adverse events.
Dr. Carmelo Carlo-Stella received his medical degree cum Laude from the University of Pavia (1981), where he also obtained the specialization in Internal Medicine (1986). He received the specialization in Hematology at the University of Parma (1993). He joined the National Cancer Institute in Milano (1999-2011), where he served as a member of the active staff in Onco-Hematology, and Director of the Hematopoietic Stem Cell Transplantation Laboratory. From 2006 to 2016, he served as Associate Professor of Medical Oncology at the University of Milano. In 2011, he joined Humanitas Research Hospital, where he is a Professor of Hematology at the Humanitas University.
Dr. Carlo-Stella has led several translational projects aimed at the preclinical development of novel agents targeting lymphoma cells and their microenvironment. Currently he uses a multi-omic approach to identify signatures of response or resistance to immunotherapy in relapsed/refractory Diffuse Large B-Cell Lymphoma. Dr. Carlo-Stella has led the study and clinical development of numerous novel antibodies in the treatment of relapsed/refractory lymphoma. He has published hundreds of original papers and reviews in leading peer-reviewed journals, including Blood, Journal of Clinical Oncology, Lancet Oncology, Cancer Research, Clinical Cancer Research, Leukemia, Bone Marrow Transplantation, and the British Journal of Hematology.
Dr. Carla Casulo is an Associate Professor at The University of Rochester’s Wilmot Cancer Institute. Dr. Casulo’s research efforts focus on Follicular Lymphoma with an emphasis on patients with early relapsed disease. Dr. Casulo is a worldwide expert on analysis of large, real world datasets that have identified risk factors and treatments for relapsed Follicular Lymphoma.
Stephane Chauvie is an Italian Medical Physicist with a post-graduate degree in Medical Physics at University of Torino and in Healthcare Management at University of Roma “La Sapienza”.
He is currently head of Medical Physics Division in Santa Croce and Carle Hospital, where he has been working since 2004. His duties include being Medical Physics Expert, Nuclear Magnetic Resonance Safety Expert, and Radiation Protection Expert.
He serves as an expert for the International Atomic Energy Agency (IAEA) and for several organs of the Italian Ministry of Economy (CONSIP) and Health (ISS and AGENAS).
Stephane is a former scientific associate of European Laboratory for Particle Physics (CERN), Italian Institute for Nuclear Physics (INFN) and European Space Agency (ESA) where was involved in Monte Carlo simulation of low-energy particle interaction with tissue at cellular level.
From 2012 he is the Head of Imaging Corelab performing Clinical Trials Qualification on behalf of Swiss Group for Clinical Cancer Research (SAKK), Spanish Lymphoma Group (GELTAMO), Polish Lymphoma Research Group (PLRG), International Extra-Nodal Lymphoma Study Group (IELSG) and Italian Foundation on Lymphoma (FIL). He has broad experience in more than 30 clinical trials as investigator (16), in the steering committee (6), as medical physicist coordinator (7) and as PI (1).
Actually, his major research topic are quantitative PET and dosimetry; he is author of 69 IF papers, 73 invited talks, 81 and 99 orals and abstracts to conference, 3 patents and is reviewer of 22 international journals with IF. Bibliometry: 47754 citations, h-index 25, i10-index 47 @ Jan14th, 2022 (google scholar)
Dr Kate Cwynarski is a Haem-Oncologist specialising in Lymphoma and CLL at University College London Hospital, London, UK. She trained at King’s College, Hammersmith Hospital and Royal Free Hospital, London UK and received her MRC-funded PhD in immunology at Imperial College, London, UK.
Her sub-specialist interests include Central Nervous System (CNS) Lymphoma, T-cell Lymphomas and HIV-related lymphoma and she is involved in CAR-T cell trials for refractory DLBCL and T-cell lymphomas.
She leads the UK T cell Lymphoma Group having previously lead the UK CNS Lymphoma Group and is a member of the National Cancer Research Institute Lymphoma Clinical Studies Group,
Dr. Cwynarski is involved in many clinical trials, has co-authored BCSH guidelines and she has authored or co-authored over 100 journal articles in Lancet Haematology,Journal of Clinical Oncology, Blood, AIDS, British Journal of Haematology and Bone Marrow Transplant
Daphne de Jong is full professor of haematopathology at AmsterdamUMC, Amsterdam, the Netherlands. She is the immediate past-president of the European Association for Haematopathology. Her focus of interest is malignant lymphoma, molecular diagnostics and clinical translational research. Since February 2021, she is one of the expert members of the editorial board for the 5th edition of the WHO Classification for Haematolymphoid Tumors.
Michael Dickinson is the Lead of the Aggressive Lymphoma disease group within Clinical Haematology at Peter MacCallum Cancer Centre and Royal Melbourne Hospital. He specialises as a principal investigator in phase I/II clinical trials of new anticancer drugs with a current focus on Aggressive Lymphomas and novel immunotherapies, Michael’s clinical research includes industry and investigator-led trials in aggressive lymphoma, phase 1 studies, and CART trials. A/Prof Dickinson is a leading investigator in pivotal clinical trials of CART for Follicular Lymphoma (ELARA, tisagenlecleucel) and DLBCL (Zuma7, Zuma12 and BELINDA). He is an investigator on phase 1 studies of CART and CAR-NK cells. Michael is heavily involved in the development of bispecific antibodies for B-cell lymphoma having dosed the first patients with glofitamab.
Dr. Dunleavy is the Director of Hematology and leader of the Lymphoma Program at Lombardi Comprehensive Cancer Center. He is a Professor of Medicine at Georgetown University, Washington DC. His clinical and research focus is lymphoma and lymphoproliferative disorders. He is a lead investigator on several lymphoma trials and serves as a member of the scientific advisory board of the Lymphoma Research Foundation. He has authored more than 150 manuscripts and book chapters focused on the biology and treatment of lymphoid diseases.
Dr Toby Eyre is a consultant haematologist at Oxford University Hospitals NHS Foundation Trust specialising in the management of lymphoid malignancies. He is an expert in the management of patients with lymphoma and patients with chronic lymphocytic leukaemia.
He has completed an MD Doctorate Thesis in early phase trials and biomarker studies in aggressive lymphoid disease in 2017. He is an investigator on a number of national UK lymphoma and chronic lymphocytic leukaemia trials and has published over 110 peer-review articles on areas of lymphoma and CLL and has presented regularly at national and international conferences.
He also has a strong interest in teaching and training and has completed a post-graduate Diploma in Medical Education. He is the current BSH-NIHR Researcher of the year in 2021.
Andrés J. M. Ferreri is Director of the Lymphoma Unit at the San Raffaele Hospital of Milan, Professor of Haematology at the University Vita-Salute of Milan, and President of the Fondazione Italiana Linfomi. He is fully devoted to the research on lymphomas, and is an opinion leader in the field of extranodal lymphomas.
Chris Fox, MBChB(Hons) PhD FRCP FRCPath, is Professor of Haematology at the University of Nottingham, UK and Honorary Consultant Haematologist at Nottingham University Hospitals NHS Trust, where he is the lead clinician for lymphoma. He is Medical Director for the UK TAP (therapy-accelerated programme) network of early phase blood cancer trials.
Prof Fox is Chair of the UK National Cancer Research Institute (NCRI) aggressive lymphoma study group and an executive committee member for the International T cell Project. He has experience as Chief Investigator for a number of academic and commercial studies. He has co-authored research papers in high-impact journals including Blood, Journal of Clinical Oncology, Nature Cancer, JAMA Oncology, Haematologica and Lancet Haematology.
Andrea Gallamini, MD, PhD, is a Consultant Hematologist at the Lacassagne Cancer Center in Nice, France. He trained in clinical research on lymphoma in Italy in S. Croce Hospital il Cuneo, and since 2013 in Sophia Antipolis University of Nice and in the Onco-hematology department of the Lacassagne Cancer Center of Nice, France. His interest includes clinical application of Imaging in Lymphoma in general, and in pathobiology and prognostication of Hodgkin Lymphoma. He has been responsible for the educational program of Imaging in Lymphoma in several annual meetings of the of European Hematology Association (EHA) and American Society of Hematology (ASH). He is Author of more than 174 scientific publications, 130 of them (76%) on Lymphoma prognostication and treatment. He is also Editor on books on Hodgkin and non-Hodgkin Lymphoma. He is at present engaged in clinical research and teaching on Lymphoma.
Nilanjan Ghosh is the Chair of Hematologic Oncology and Blood Disorders, Chief of the Lymphoma division and Professor of Medicine at Levine Cancer Institute, Atrium health, Charlotte, NC. His research interests include development of targeted therapies in lymphoma and CLL, role of cellular therapies and transplantation in lymphoma, mechanisms of resistance to immunotherapies and overcoming organ dysfunction and disparities of care.
Maria Gomes da Silva is Professor of Haematology at the NOVA Medical School and a Senior Consultant in Clinical Haematology at the Haematology Department of the Portuguese Institute of Oncology in Lisbon, where she is also Head of the Haemato-Oncology Unit. She received her medical degree from the Faculdade de Medicina de Lisboa, and her PhD in Medicine from NOVA Medical School. Her research interests focus on the biology and treatment of lymphoid neoplasias.
Professor Gomes da Silva is Vice President of the Portuguese Society of Haematology since 2021 and chairs the Portuguese Lymphoma Group. She is a member of the American Society of Haematology, European Hematology Association, the Lymphoma Study Association, the European Mantle Cell Network, the European Lymphoma Institute (board of directors) and of the Lymphoma Scientific Working Group of the European Lymphoma Association. She has been a principal investigator of several Phase II/III clinical trials focused in the treatment of lymphomas, and has authored and co-authored more than 70 scientific publications in different journals including Lancet, New England Journal of Medicine, Blood, Annals of Oncology and Haematologica.
A/Prof Hawkes is the Lymphoma Lead at the Olivia Newton John Cancer Centre, Austin Health in Melbourne Australia. She is Lymphoma co-chair for the National cooperative trials ‘Australasian Leukaemia and Lymphoma Group’ (ALLG), founded the Australasian Lymphoma Alliance, and is a founding steering committee member of the international Women in Lymphoma group, Australian Lymphoma Registry, American Society of Clinical Oncology education committee and participates in numerous international working groups and research initiatives.
A/Prof Hawkes’ own research interest is in real-world evidence to inform trial design and therapeutic immune manipulation for lymphoma with biomarker-driven novel combination treatments. She is passionate about mentoring junior investigators in clinical research.
Dr. Jacobson is a lymphoma clinical investigator at the Dana-Farber Cancer Institute, and her research interests are in immunotherapies for the treatment of B-cell non-Hodgkin lymphoma. She is the principal investigator of several CAR T-cell therapy studies and has authored numerous peer-reviewed publications. She currently is an Assistant Professor of Medicine at Harvard Medical School and serves as the Medical Director of the Immune Effector Cell Therapy Program at the Dana-Farber Cancer Institute, which houses the commercial and research cell therapy programs for solid and hematologic malignancies across the institute.
Mats Jerkeman is Professor in Clinical Oncology at Lund University, Sweden. Professor Jerkeman is also Chairman of the Nordic Lymphoma Group, Vice Chair of the European Mantle Cell Lymphoma Network. His research focuses on improving the quality of life and survival of patients with malignant lymphomas. He completed his doctoral training at Lund University, Sweden.
Professor Jerkeman is the Coordinator of several ongoing clinical trials in diffuse large B-cell lymphoma and mantle cell lymphoma, is Chairman of the National Guidelines for Lymphoma, Sweden and has also served as coordinator of the Swedish Lymphoma Register for many years. He is Editor of the European Society of Medical Oncology Lymphoma Guidelines for lymphoma. He has over 150 publications in peer-reviewed journals.
residency in Internal Medicine and a fellowship in Hematology and Oncology at the East Carolina University in Greenville, North Carolina. I then completed another fellowship in lymphoid malignancies and bone marrow transplantation at Stanford University. Subspecializing in lymphomas appealed to me because of the clinical heterogeneity with each subtype, scientifically stimulating biology, opportunity to tailor therapeutics, and the endless possibilities of new drug development. Currently, I am an Associate Professor of Medicine at the University of Colorado School of Medicine and serve as the Clinical Director of the lymphoma program. My clinical and research interests include Bcell lymphomas, particularly refractory diffuse large B-cell lymphoma, mantle cell lymphomas, and other indolent lymphomas. In addition to seeing patients with lymphoma in clinic, my research involves conducting clinical trials of novel drugs, including immunotherapy and combinations in these diseases. I have had the opportunity to serve in organizations at the national level. This includes working with the National Comprehensive Cancer Network guidelines committee and Southwest Oncology Group lymphoma committee, where I serve as a cadre member of the chronic lymphocytic leukemia and lymphoma working groups, respectively. My goal is to develop nuanced approaches of personalized medicine in lymphoid malignancies, and I am currently collaborating with several clinical as well as laboratory-based investigators in the United States. My eventual hope is to make these fascinating discoveries efficacious, durable, and affordable so that they have a far-reaching impact on patients everywhere.
Marie José Kersten is a professor of hematology at the department of Hematology at Amsterdam UMC in Amsterdam. B cell malignancies are the main focus of research in this department, which together with the departments of Pathology and Experimental Immunology forms the basis for the LYMMCARE Institute (Lymphoma and Myeloma Center Amsterdam). Marie José Kersten is involved in several research projects and she is the principal investigator for several phase I/II clinical trials focusing on the biology and treatment of NHL, Waldenstrom’s macroglobulinemia and Hodgkin lymphoma. She is the chair of the EHA (European Hematology Association) Scientific Working Group Lymphoma and a co-founder and chair of the Lunenburg Lymphoma Phase I/II Consortium (LLPC). The main focus of the LLPC is to perform early clinical trials (from first-in-man trials to early phase II trials) in patients with lymphoma. She has been and is involved in many CAR T-cell clinical trials and in several research projects concerning side effects and quality of life in CAR T-cell treated patients.
Dr. Kharfan-Dabaja is a Professor of Medicine, Vice-Chair of Hematology, and the Director of the Blood and Marrow Transplantation and Cellular Immune Therapies programs at Mayo Clinic in Jacksonville, FL. His main interests are chimeric antigen receptor T-cell (CAR-T) therapy for lymphoid neoplasms and reduced intensity allogeneic hematopoietic cell transplantation for various hematologic malignancies. He is Board certified in Medical Oncology, Hematology and Internal Medicine. He is a co-Chair of the Lymphoma Working Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR), the chair of the Payer Relation Committee and a member of the Clinical Practice Guidelines Committee of the American Society for Transplantation and Cellular Therapy, and a member of the Committee on Investment and Audit of the American Society of Hematology. He has published over 350 peer-reviewed manuscripts, 21 book chapters and has presented his work at various regional, national and international scientific platforms.
Dr. John Kuruvilla is an Associate Professor of Medicine at the University of Toronto and a hematologist in the Division of Medical Oncology and Hematology at the Princess Margaret Cancer Centre in Toronto. He is a member of the Lymphoma, Autologous Transplant and Immune Effector Cell Therapy programs and Co-Director of the Beyond Chemotherapy Program.
Dr. Kuruvilla’s research interest is the development of novel therapeutics in lymphoid malignancies and incorporating translational research into clinical trials. He is the Lymphoma Co-Chair for the Canadian Cancer Trials Group (CCTG) as well as the Chair of the Scientific Advisory Board of Lymphoma Canada.
Dr Lim is Associate Professor and Honorary Consultant in Haematological Oncology at the University of Southampton. She is a practising clinician specialising in lymphoma and a research group leader. Her research group focuses on discovery of novel antibody-based therapeutic targets and understanding the mechanisms behind monoclonal antibody therapeutics. She is lead and co-lead to multiple COVID-19 vaccine studies (PROSECO, OCTAVE-DUO, MELODY) in immunocompromised individuals.
Dr Roya Merie is a consultant radiation oncologist at Icon Cancer Centre, Concord Hospital, Australia. She undertook her radiation oncology training at Liverpool and St George Hospitals in Sydney followed by fellowship in thoracic malignancies at Liverpool Hospital with research focus on radiotherapy utilisation and health service planning. She has special interest in treating haematological, gastrointestinal and thoracic malignancies.
Alberto Mussetti MD, works at the Hematology Department at Institut Català d’Oncologia (Barcelona, Spain) as Director of the Hematopoietic Cell Transplantation and Cell Therapy Unit. During the last years his research has been focused on lymphoid malignancies, allogeneic hematopoietic cell transplant and digital medicine. He previously worked at Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy). Apart from his expertise in allogeneic hematopoietic cell transplantation, Alberto Mussetti received a basic laboratory training and a professional clinical training in chimeric antigen receptor (CAR) therapy during a fellowship in 2013-2014 at the Memorial Sloan Kettering Cancer Center of New York. At Institut Català d’Oncologia he helped building the cell therapy program and he started treating the first patients of the center with CAR T cells in the context of international clinical trials and commercial use. He is an active participant and principal investigator of the Lymphoma Working party of the European Bone Marrow Transplantation Society (EBMT) and the Center for International Bone Marrow Transplant Research (CIBMTR).
Dr. Lakshmi Nayak serves as Director of the Center for Central Nervous System (CNS) Lymphoma at Dana-Farber Cancer Institute in Boston. She is an Assistant Professor of Neurology at Harvard Medical School. She received her medical degree from Grant Medical College in Mumbai, India. She completed her residency at New York Presbyterian Hospital/ Cornell campus, and fellowship at Memorial Sloan-Kettering Cancer Center in New York. Her research includes development of novel therapies through preclinical and clinical studies for management of brain tumors including primary CNS lymphoma. She has developed several phase I and II trials using combination of molecular targeted agents and immunotherapies including checkpoint inhibitors and CAR T cells for treatment of CNS lymphomas. She leads the international neurologic assessment in neuro-oncology (NANO) effort in collaboration with key leaders in neuro-oncology which led to the development of a standardized outcome-assessment scale to objectively evaluate neurologic function in patients with brain tumors.
Dr Wendy Osborne is a Consultant Haematologist at the Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust. She graduated with First Class Honours from Newcastle University in 1998 and completed her General Medical Training at Queens Medical Centre, Nottingham. Dr Osborne worked in haematology departments in Glasgow before returning to Newcastle to undertake Higher Specialist Training.
Dr Osborne is Chair of the British Society of Haematology Lymphoma Special Interest Group and a member of the NCRI Clinical Studies Group, High Grade lymphoma sub-group, Hodgkin lymphoma subgroup. Dr Osborne is on the medical advisory panel for Lymphoma Action and is a principal investigator and co-investigator for numerous clinical trials. Dr Osborne is the teaching lead for the haematology undergraduate programme at Newcastle University and was appointed as an Associate Lecturer in 2016.
Mazyar Shadman, MD, MPH, is an associate professor at University of Washington (UW) and Fred Hutchinson Cancer Center (FHCC). He is a hematologic malignancies expert who specializes in treating patients with lymphoma/ chronic lymphocytic leukemia (CLL).
He is involved in clinical trials using novel therapeutic agents, immunotherapy (CAR-T cell), and stem cell transplant for treatment of lymphoid malignancies with a focus on CLL. He also studies the clinical outcomes of patients using institutional and collaborative retrospective cohort studies.
Dr. Shadman received his M.D. from Tehran University in Iran. He finished internal medicine internship and residency training at the Cleveland Clinic in Cleveland, Ohio. He returned to Seattle and completed his training in hematology and medical oncology fellowships at the UW and Fred Hutchinson Cancer Center. Dr. Shadman also earned an M.P.H. degree from UW and was a fellow for National Cancer Institute’s cancer research training program at Fred Hutch, where he studies cancer epidemiology.
Dr Matthew Wilson is a Consultant Haematologist and Honorary Clinical Senior Lecturer at the Queen Elizabeth University Hospital in Glasgow, where he specialises in lymphoma and cellular therapy. He completed haematology training in Glasgow, including a fellowship in lymphoma at the Beatson West of Scotland Cancer Centre, as well as completing a diploma in lymphoid malignancies with the European School of Oncology. He has a particular interest in the prevention and management of secondary CNS lymphoma with a number of publications and international presentations on the subject.
This site place cookies on your machine for reasons including keeping track of your preferences, collecting aggregated statistics to analyze how our site is used, and to show you ads tailored to your interests. ACCEPT
Privacy, Cookies Policy, General Terms and Conditions of Use
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.